EXTAVIA Approved In European Union For Treatment Of Multiple Sclerosis, First In Planned Portfolio Of Therapies From Novartis May 28, 2008
If you're new here, you may want to subscribe to my RSS feed. Thanks for visiting!
The European Commission has approved Extavia® (interferon beta-1b) for the treatment of early and relapsing forms of multiple sclerosis (MS) – the first in a new portfolio of medicines from Novartis that is planned to include both established treatments and innovative therapies for patients with MS. Extavia is the Novartis branded version of interferon beta-1b, a first-line disease-modifying therapy injected every other day for the treatment of MS.
add to del.icio.us
Print This Post
RSS
Leave a Reply